Filing Flows › Syndax Pharmaceuticals (SNDX) › Q3 2026 › vs Q3 2025
Syndax Pharmaceuticals (SNDX) Q3 2026 vs Q3 2025 (year over year)
Syndax Pharmaceuticals's revenue rose $37.4M (+82%) from $45.9M in Q3 2025 to $83.3M in Q3 2026. The biggest changes: Product +$28.7M (+90%); Collaboration Revenue +$8.7M (+63%).
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $60.7M | $32.0M | $28.7M | +90% |
| Collaboration Revenue | $22.6M | $13.9M | $8.7M | +63% |
| Revenue | $83.3M | $45.9M | $37.4M | +82% |
| Net loss | $49.4M | $60.7M | −$11.3M | -19% |
| Costs & expenses | $133M | $107M | $26.1M | +25% |
| Operating costs | $125M | $103M | $21.9M | +21% |
| Interest & other, net | $7.5M | $3.3M | $4.2M | +129% |
| Research & development | $67.5M | $56.3M | $11.2M | +20% |
| General & admin | $43.7M | $44.9M | −$1.2M | -3% |
| Other operating costs | $14.0M | $2.1M | $11.9M | +566% |
| Operating cash sources | $49.4M | $60.7M | −$11.3M | -19% |
| Depreciation | $6.0M | $3.0M | $3.0M | +100% |
| Share-based compensation | $15.3M | $12.1M | $3.2M | +27% |
| Working capital & other | $892K | −$24.9M | $25.8M | — |
| Cash used in operations | $27.3M | $70.5M | −$43.3M | -61% |
| Net loss absorbed | $49.4M | $60.7M | −$11.3M | -19% |
Questions
How much did Syndax Pharmaceuticals's revenue grow year over year in Q3 2026?
Syndax Pharmaceuticals's revenue rose $37.4M (+82%) from $45.9M in Q3 2025 to $83.3M in Q3 2026.
What drove Syndax Pharmaceuticals's revenue change in Q3 2026?
Product +$28.7M (+90%); Collaboration Revenue +$8.7M (+63%).